Stephens Investment Management Group LLC Buys 18,786 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Stephens Investment Management Group LLC lifted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 139,420 shares of the company’s stock after purchasing an additional 18,786 shares during the quarter. Stephens Investment Management Group LLC owned about 0.45% of Medpace worth $46,320,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Pallas Capital Advisors LLC increased its position in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Baillie Gifford & Co. raised its position in Medpace by 175.6% in the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock worth $4,966,000 after purchasing an additional 9,478 shares during the period. Barclays PLC lifted its stake in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Medpace by 6.3% during the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock valued at $15,179,000 after buying an additional 2,675 shares during the period. Finally, CWA Asset Management Group LLC bought a new position in shares of Medpace during the third quarter valued at approximately $1,306,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of research analyst reports. Truist Financial decreased their price target on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. TD Cowen dropped their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $354.10 on Friday. The business has a fifty day moving average price of $343.88 and a 200 day moving average price of $349.80. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock has a market capitalization of $11.01 billion, a P/E ratio of 31.01, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.